EICHORCondition: Healthy · Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.
Sponsor, CRO or site team? See where this study is running → — listed sites, countries and recruiting context. Everything below is written for patients and caregivers.
The purpose of this study is to determine the effects of a potent CYP3A4 inhibitor, itraconazole, on the steady-state PK of AVP-923 and AVP-786.
This description comes directly from the study's public registry record.
No contact information is available for this study as per the public registry record.
Always discuss trial participation with your own doctor first.
Inclusion Criteria: * Healthy adult males and females, 18 to 55 years of age * Body Mass Index (BMI) ≥19 and ≤30 kg/m2 (for both males and females) Exclusion Criteria: * History or presence of significant disease * History of substance abuse or dependence (except caffeine), or treatment for substance use disorder(s) within the year prior to screening or within 6 months for nicotine including e-cigarettes * Use of any tobacco-containing or nicotine-containing products within 6 months prior to the first dose * Use of any prescription or the over-the-counter medications within 14 days
Reproduced word-for-word from the public registry record — the study team can answer questions about it.
| Vince and Associates Clinical Research, Inc. | Overland Park, Kansas, United States | — |
This study lists sites in the areas below. Each link shows other recruiting studies near that city, from the public registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT02402595